IP Library Granted Patent US 9,079,904
Granted Patent B2
US 9,079,904 · App. 12/889,323 · Granted Jul 14, 2015

Pyrido[3,4-B]indoles and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,079,904
App. No.
12/889,323
Granted
Jul 14, 2015
Kind
B2
Abstract

This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

Claims (135)

1. A compound of the formula (I):

wherein:

R 1 and R 2a are taken together to form an ethylene (—CH 2 CH 2 —) moiety;

R 2b is H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, hydroxyl, alkoxy, or nitro;

each R 3a and R 3b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, nitro, hydroxyl, alkoxy, substituted or unsubstituted amino, cycloalkyl, aryl, heteroaryl, heterocyclyl, acylamino or acyloxy or R 3a and R 3b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety;

each R 10a and R 10b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, hydroxyl, alkoxy, cyano, nitro or R 10a and R 10b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety;

each X 7 , X 8 , X 9 and X 10 is independently CR 4 ;

each R 4 is independently H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

q is 0 or 1;

m is 1;

n is 1;

each R 8a , R 8b , R 8c , R 8d , R 8e and R 8f is independently H, hydroxyl, alkoxy, halo, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 8 alkenyl, C 1 -C 8 perhaloalkyl, carboxyl, carbonylalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or is taken together with a geminal R 8(a-f) to form a substituted or unsubstituted methylene moiety or a moiety of the formula —OCH 2 CH 2 O—, or is taken together with a geminal R 8(a-f) and the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety, or is taken together with a vicinal R 8(a-f) and the carbon atoms to which they are attached to form a substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, or substituted or unsubstituted heterocyclyl moiety, or is taken together with a vicinal R 8(a-f) to form a bond provided when an R 8(a-f) is taken together with a vicinal R 8(a-f) to form a bond, the geminal R 8(a-f) is other than hydroxyl; and

Q is substituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, alkoxy, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, cyano, alkynyl, aminocarbonylalkoxy or acylamino;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein q is 0 and m is 1, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein X 7 , X 8 and X 10 are CR 4 where R 4 is H, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein X 8 and X 10 are CR 4 where R 4 is H; q is 0; and R 8c and R 8d are both H, or a pharmaceutically acceptable salt thereof.

5. A compound of the formula (A):

wherein:

R 1 and R 2a are taken together to form an ethylene (—CH 2 CH 2 —) moiety

H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, hydroxyl, alkoxy, or nitro;

each R 3a and R 3b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, nitro, hydroxyl, alkoxy, substituted or unsubstituted amino, cycloalkyl, aryl, heteroaryl, heterocyclyl, acylamino or acyloxy or R 3a and R 3b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety;

each R 10a and R 10b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, hydroxyl, alkoxy cyano, nitro, or R 10a and R 10b are taken together with the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety;

each X 7 , X 8 , X 9 and X 10 is independently CR 4 ;

each R 4 is independently H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

m and q are independently 0 or 1;

each R 8a , R 8b , R 8c and R 8d is independently H, hydroxyl, halo, alkoxy, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 8 alkenyl, C 1 -C 8 perhaloalkyl, carboxyl, carbonylalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or is taken together with a geminal R 8(a-d) to form a substituted or unsubstituted methylene moiety or a moiety of the formula —OCH 2 CH 2 O—, or is taken together with a geminal R 8(a-d) and the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety;

each R 11 and R 12 is independently H, halo, alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, carboxy, carbonylalkoxy or C 1 -C 8 perhaloalkyl and the bond indicates the presence of either an E or Z double bond configuration, or R 11 and R 12 are taken together to form a bond or are taken together with the carbon atoms to which they are attached to form a substituted or unsubstituted C 3-8 cycloalkenyl or substituted or unsubstituted heterocyclyl moiety; and

Q is substituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, alkoxy, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, cyano, alkynyl, aminocarbonylalkoxy or acylamino;

or a pharmaceutically acceptable salt thereof.

6. A compound of the formula (II):

wherein

R 2b is H, halo, or substituted or unsubstituted C 1 -C 8 alkyl;

each R 3a and R 3b is independently H, halo, or substituted or unsubstituted C 1 -C 8 alkyl;

each R 10a and R 10b is independently H, halo, or a substituted or unsubstituted C 1 -C 8 alkyl;

p is 1;

each X 7 , X 8 , X 9 and X 10 is independently CR 4 ;

each R 4 is independently H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

q is 0 or 1;

m is 1;

n is 1;

each R 8a , R 8b , R 8c , R 8d , R 8e and R 8f is independently H, hydroxyl, alkoxy, halo, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 8 alkenyl, C 1 -C 8 perhaloalkyl, carboxyl, carbonylalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or is taken together with a geminal R 8(a-f) to form a substituted or unsubstituted methylene moiety or a moiety of the formula —OCH 2 CH 2 O—, or is taken together with a geminal R 8(a-f) and the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety, or is taken together with a vicinal R 8(a-f) and the carbon atoms to which they are attached to form a substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, or substituted or unsubstituted heterocyclyl moiety, or is taken together with a vicinal R 8(a-f) to form a bond provided when an R 8(a-f) is taken together with a vicinal R 8(a-f) to form a bond, the geminal R 8(a-f) is other than hydroxyl; and

Q is a substituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, alkoxy, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, cyano, alkynyl, aminocarbonylalkoxy or acylamino;

or a pharmaceutically acceptable salt thereof.

7. A compound of the formula (B):

wherein:

R 2b is H, n halo, or substituted or unsubstituted C 1 -C 8 alkyl;

each R 3a and R 3b is independently H, halo, or substituted or unsubstituted C 1 -C 8 alkyl;

each R 10a and R 10b is independently H, halo, or a substituted or unsubstituted C 1 -C 8 alkyl;

p is 1;

each X 7 , X 8 , X 9 and X 10 is independently CR 4 ;

each R 4 is independently H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

m and q are independently 0 or 1;

each R 8a , R 8b , R 8c and R 8d is independently H, hydroxyl, alkoxy, halo, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 8 alkenyl, C 1 -C 8 perhaloalkyl, carboxyl, carbonylalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or is taken together with a geminal R 8(a-d) to form a substituted or unsubstituted methylene moiety or a moiety of the formula —OCH 2 CH 2 O—, or is taken together with a geminal R 8(a-d) and the carbon to which they are attached to form a carbonyl moiety or a cycloalkyl moiety;

each R 11 and R 12 is independently H, halo, alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, carboxy, carbonylalkoxy or C 1 -C 8 perhaloalkyl and the bond indicates the presence of either an E or Z double bond configuration, or R 11 and R 12 are taken together to form a bond or are taken together with the carbon atoms to which they are attached to form a substituted or unsubstituted C 3-8 cycloalkenyl or substituted or unsubstituted heterocyclyl moiety; and

Q is a substituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, alkoxy, aminoacyl, acyloxy, carboxyl, carbonylalkoxy, cyano, alkynyl, aminocarbonylalkoxy or acylamino;

or a pharmaceutically acceptable salt thereof.

8. A compound selected from compounds 1-3 and 5-7,

Compound #

Structure

1

2

3

5

6

7

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising (a) a compound of claim 1 or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier.

10. A kit comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is selected from the group consisting of Compound Nos. 1-3, 5-45 and 71-73,

Compound #

Structure

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

71

72

73

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein the compound is of the formula G-1:

wherein:

R 4 is methyl;

R 8c is H, hydroxyl, or methyl;

R 8d is H, or methyl;

or R 8c and R 8d are taken together to form a methylene moiety or an oxo moiety; and

Q is substituted or unsubstituted pyridyl; substituted phenyl; substituted or unsubstituted phenylthiazole; substituted or unsubstituted piperidyl; substituted or unsubstituted piperazinyl; substituted or unsubstituted morpholinyl or substituted amino;

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is of the formula (Ii-5), (Ii-6) or (Ii-7):

wherein:

R 4 is halo or C 1 -C 8 alkyl;

R 9 is H or CH 3 ; and

R 8f is H or CH 3 ;

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13 , wherein R 4 is halo or CH 3 ; or a pharmaceutically acceptable salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 28, 2016
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MEDIVATION PROSTATE THERAPEUTICS, INC.; MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 040181/0177 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 4, 2015
From: MEDIVATION TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036553/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2010
From: JAIN, RAJENDRA PARASMAL; CHAKRAVARTY, SARVAJIT
To: MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 025507/0533 →